BioEnterprise has named Aram Nerpouni as the group's interim president, starting next month. Nerpouni replaces Baiju Shah who is leaving BioEnterprise to run a drug development company.
Clik here to view.
View full sizeAram Nerpouni will become the interim president of BioEnterprise on Sept. 1. Nerpouni replaces Baiju Shah who is leaving the economic development group to run a startup drug company.CLEVELAND, Ohio -- Medical economic development group BioEnterprise has named long-time group executive Aram Nerpouni as its interim president starting next month.
The group's long-time president Baiju Shah, announced last month that he was stepping down to become chief executive of BioMotiv, a drug development company that spun out of University Hospitals.
Nerpouni rejoined BioEnterprise earlier this year after leaving to become chief administration officer of Akron's Austen BioInnovation Institute. Before joining that group, Nerpouni had been with BioEnterprise, where he worked with Akron area biomedical companies and institutions.
Joseph Scaminace, chairman of BioEnterprise's board, vice chairman of the Cleveland Clinic and chief executive of specialty chemicals company OM Group, said Nerpouni was the logical choice to become the group's interim president.
"Through his leadership role in a number of strategic, industry-accelerating projects in the region, he has demonstrated his ability to convene and collaborate with stakeholders across the region towards a common goal of growing Northeast Ohio's biomedical industry," Scaminace said in a prepared statement.
BioEnterprise did not say how long Nerpouni's job would be considered interim. In an email, Scaminace said the group is not conducting a search for a new leader at this time.
"The board looks forward to working with Aram Nerpouni during this important transition, Scaminace said in the email.
Shah joined BioEnterprise in 2002 and became its president in 2004. Nerpouni earned his undergraduate degree in biology from Stanford University and his Masters in Business Administration at Case Western Reserve University. BioEnterprise got its start at Case in the late 1990s before spinning off into an independent group.
"Due to the collaboration and commitment of many, the region is now a nationally recognized center for biomedical innovation," Nerpouni said in a prepared statement. "There is a strong foundation on which to accelerate the industry's growth for years to come."
